{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T14:04:07Z","timestamp":1790949847537,"version":"4.1.0"},"reference-count":44,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,10,7]],"date-time":"2024-10-07T00:00:00Z","timestamp":1728259200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["academicradiology.org","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Academic Radiology"],"published-print":{"date-parts":[[2025,8]]},"DOI":"10.1016\/j.acra.2024.09.061","type":"journal-article","created":{"date-parts":[[2024,10,9]],"date-time":"2024-10-09T06:59:10Z","timestamp":1728457150000},"page":"4595-4606","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":14,"title":["Efficacy and Safety of HAIC-FOLFOX Plus Tyrosine Kinase Inhibitors and Immune Checkpoint Inhibitors as First-line Treatment for Unresectable Advanced Hepatocellular Carcinoma: A Systematic Review and Meta-Analysis"],"prefix":"10.1016","volume":"32","author":[{"ORCID":"https:\/\/orcid.org\/0009-0004-6177-1201","authenticated-orcid":false,"given":"Peng","family":"Jiang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chao","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Tian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fan","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhen-yu","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"An-xiang","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bin","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.acra.2024.09.061_bib1","first-page":"229","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray","year":"2024","journal-title":"CA Cancer J Clin"},{"issue":"4","key":"10.1016\/j.acra.2024.09.061_bib2","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1001\/jamasurg.2022.7989","article-title":"Management of hepatocellular carcinoma: a review","volume":"158","author":"Brown","year":"2023","journal-title":"JAMA Surg"},{"issue":"3","key":"10.1016\/j.acra.2024.09.061_bib3","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1053\/j.gastro.2021.06.008","article-title":"Evidence-based management of hepatocellular carcinoma: systematic review and meta-analysis of randomized controlled trials (2002-2020)","volume":"161","author":"Haber","year":"2021","journal-title":"Gastroenterology"},{"issue":"4","key":"10.1016\/j.acra.2024.09.061_bib4","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1016\/j.cld.2020.07.012","article-title":"Tyrosine kinase inhibitors and hepatocellular carcinoma","volume":"24","author":"da Fonseca","year":"2020","journal-title":"Clin Liver Dis"},{"issue":"20","key":"10.1016\/j.acra.2024.09.061_bib5","doi-asserted-by":"crossref","first-page":"1894","DOI":"10.1056\/NEJMoa1915745","article-title":"Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma","volume":"382","author":"Finn","year":"2020","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1016\/j.acra.2024.09.061_bib6","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1016\/j.jhep.2021.11.030","article-title":"Updated efficacy and safety data from IMbrave150: atezolizumab plus bevacizumab vs. sorafenib for unresectable hepatocellular carcinoma","volume":"76","author":"Cheng","year":"2022","journal-title":"J Hepatol"},{"key":"10.1016\/j.acra.2024.09.061_bib7","doi-asserted-by":"crossref","first-page":"1497","DOI":"10.2147\/JHC.S418387","article-title":"Hepatic arterial infusion chemotherapy combined with lenvatinib plus humanized programmed death receptor-1 in patients with high-risk advanced hepatocellular carcinoma: a real-world study","volume":"10","author":"Chang","year":"2023","journal-title":"J Hepatocell Carcinoma"},{"key":"10.1016\/j.acra.2024.09.061_bib8","doi-asserted-by":"crossref","first-page":"b2700","DOI":"10.1136\/bmj.b2700","article-title":"The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration","volume":"339","author":"Liberati","year":"2009","journal-title":"BMJ"},{"issue":"10","key":"10.1016\/j.acra.2024.09.061_bib9","first-page":"2127","article-title":"Methodological quality of case series studies: an introduction to the JBI critical appraisal tool","volume":"18","author":"Munn","year":"2020","journal-title":"JBI Evid Synth."},{"issue":"1","key":"10.1016\/j.acra.2024.09.061_bib10","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/S1055-3207(02)00082-0","article-title":"Results of hepatic resection for hepatocellular carcinoma invading major portal and\/or hepatic veins","volume":"12","author":"Ikai","year":"2003","journal-title":"Surg Oncol Clin N Am"},{"issue":"2","key":"10.1016\/j.acra.2024.09.061_bib11","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1016\/j.hbpd.2021.12.004","article-title":"Management of hepatocellular carcinoma patients with portal vein tumor thrombosis: a narrative review","volume":"21","author":"Tao","year":"2022","journal-title":"Hepatobiliary Pancreat Dis Int"},{"key":"10.1016\/j.acra.2024.09.061_bib12","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.2147\/JHC.S417550","article-title":"Hepatic arterial infusion chemotherapy plus lenvatinib and tislelizumab with or without transhepatic arterial embolization for unresectable hepatocellular carcinoma with portal vein tumor thrombus and high tumor burden: a multicenter retrospective study","volume":"10","author":"Chen","year":"2023","journal-title":"J Hepatocell Carcinoma"},{"key":"10.1016\/j.acra.2024.09.061_bib13","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.929141","article-title":"Efficacy and safety of atezolizumab plus bevacizumab combined with hepatic arterial infusion chemotherapy for advanced hepatocellular carcinoma","volume":"13","author":"Xin","year":"2022","journal-title":"Front Immunol"},{"issue":"17","key":"10.1016\/j.acra.2024.09.061_bib14","doi-asserted-by":"crossref","first-page":"2321","DOI":"10.3748\/wjg.v30.i17.2321","article-title":"Efficacy and safety of targeted therapy plus immunotherapy combined with hepatic artery infusion chemotherapy (FOLFOX) for unresectable hepatocarcinoma","volume":"30","author":"Lin","year":"2024","journal-title":"World J Gastroenterol"},{"issue":"9","key":"10.1016\/j.acra.2024.09.061_bib15","doi-asserted-by":"crossref","DOI":"10.1002\/cam4.7105","article-title":"Hepatic arterial infusion chemotherapy, lenvatinib plus programmed cell death protein-1 inhibitors: a promising treatment approach for high-burden hepatocellular carcinoma","volume":"13","author":"Fu","year":"2024","journal-title":"Cancer Med"},{"issue":"1","key":"10.1016\/j.acra.2024.09.061_bib16","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1038\/s41392-023-01663-6","article-title":"Camrelizumab (a PD-1 inhibitor) plus apatinib (an VEGFR-2 inhibitor) and hepatic artery infusion chemotherapy for hepatocellular carcinoma in Barcelona Clinic Liver Cancer stage C (TRIPLET): a phase II study","volume":"8","author":"Zhang","year":"2023","journal-title":"Signal Transduct Target Ther"},{"key":"10.1016\/j.acra.2024.09.061_bib17","doi-asserted-by":"crossref","DOI":"10.1177\/17588359211002720","article-title":"Lenvatinib, toripalimab, plus hepatic arterial infusion chemotherapy versus lenvatinib alone for advanced hepatocellular carcinoma","volume":"13","author":"He","year":"2021","journal-title":"Ther Adv Med Oncol"},{"issue":"1","key":"10.1016\/j.acra.2024.09.061_bib18","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1186\/s12885-024-12233-6","article-title":"HAIC Combined with lenvatinib plus PD-1 versus lenvatinib Plus PD-1 in patients with high-risk advanced HCC: a real-world study","volume":"24","author":"Chang","year":"2024","journal-title":"BMC Cancer"},{"issue":"4","key":"10.1016\/j.acra.2024.09.061_bib19","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1007\/s00535-023-01976-x","article-title":"Induction therapy with hepatic arterial infusion chemotherapy enhances the efficacy of lenvatinib and pd1 inhibitors in treating hepatocellular carcinoma patients with portal vein tumor thrombosis","volume":"58","author":"Fu","year":"2023","journal-title":"J Gastroenterol"},{"issue":"1","key":"10.1016\/j.acra.2024.09.061_bib20","doi-asserted-by":"crossref","first-page":"1126","DOI":"10.1186\/s12885-021-08858-6","article-title":"Pembrolizumab plus lenvatinib with or without hepatic arterial infusion chemotherapy in selected populations of patients with treatment-naive unresectable hepatocellular carcinoma exhibiting PD-L1 staining: a multicenter retrospective study","volume":"21","author":"Chen","year":"2021","journal-title":"BMC Cancer"},{"key":"10.1016\/j.acra.2024.09.061_bib21","doi-asserted-by":"crossref","first-page":"2211","DOI":"10.2147\/JHC.S441024","article-title":"The safety and efficacy of hepatic arterial infusion chemotherapy combined with PD-(L)1 inhibitors and molecular targeted therapies for the treatment of intermediate and advanced hepatocellular carcinoma unsuitable for transarterial chemoembolization","volume":"10","author":"Tang","year":"2023","journal-title":"J Hepatocell Carcinoma"},{"key":"10.1016\/j.acra.2024.09.061_bib22","doi-asserted-by":"crossref","DOI":"10.1007\/s12072-024-10672-8","article-title":"Hepatic artery infusion chemotherapy combined with camrelizumab plus rivoceranib for hepatocellular carcinoma with portal vein tumor thrombosis: a multicenter propensity score-matching analysis","author":"Li","year":"2024","journal-title":"Hepatol Int"},{"issue":"4","key":"10.1016\/j.acra.2024.09.061_bib23","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1056\/NEJMoa0708857","article-title":"Sorafenib in advanced hepatocellular carcinoma","volume":"359","author":"Llovet","year":"2008","journal-title":"N Engl J Med"},{"issue":"7","key":"10.1016\/j.acra.2024.09.061_bib24","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1001\/jamaoncol.2019.0250","article-title":"Sorafenib plus hepatic arterial infusion of oxaliplatin, fluorouracil, and leucovorin vs sorafenib alone for hepatocellular carcinoma with portal vein invasion: a randomized clinical trial","volume":"5","author":"He","year":"2019","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.acra.2024.09.061_bib25","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.2147\/JHC.S318070","article-title":"Portal vein tumor thrombosis and hepatocellular carcinoma - the changing tides","volume":"8","author":"Khan","year":"2021","journal-title":"J Hepatocell Carcinoma"},{"key":"10.1016\/j.acra.2024.09.061_bib26","doi-asserted-by":"crossref","first-page":"1085166","DOI":"10.3389\/fonc.2023.1085166","article-title":"Hepatic arterial infusion chemotherapy versus sorafenib for advanced hepatocellular carcinoma with portal vein tumor thrombus: an updated meta-analysis and systematic review","volume":"13","author":"Zhang","year":"2023","journal-title":"Front Oncol"},{"issue":"4","key":"10.1016\/j.acra.2024.09.061_bib27","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1159\/000473887","article-title":"Sorafenib versus hepatic arterial infusion chemotherapy as initial treatment for hepatocellular carcinoma with advanced portal vein tumor thrombosis","volume":"6","author":"Moriguchi","year":"2017","journal-title":"Liver Cancer"},{"issue":"1","key":"10.1016\/j.acra.2024.09.061_bib28","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1007\/s12072-023-10599-6","article-title":"Arterial chemotherapy for hepatocellular carcinoma in China: consensus recommendations","volume":"18","author":"Zhao","year":"2024","journal-title":"Hepatol Int"},{"issue":"3","key":"10.1016\/j.acra.2024.09.061_bib29","doi-asserted-by":"crossref","first-page":"593","DOI":"10.3350\/cmh.2022.0391","article-title":"Hepatic arterial infusion chemotherapy for advanced hepatocellular carcinoma in the era of chemo-diversity","volume":"29","author":"Iwamoto","year":"2023","journal-title":"Clin Mol Hepatol"},{"issue":"4","key":"10.1016\/j.acra.2024.09.061_bib30","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1172\/JCI40269","article-title":"Chemotherapy enhances tumor cell susceptibility to CTL-mediated killing during cancer immunotherapy in mice","volume":"120","author":"Ramakrishnan","year":"2010","journal-title":"J Clin Invest"},{"issue":"11","key":"10.1016\/j.acra.2024.09.061_bib31","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1158\/2326-6066.CIR-16-0197","article-title":"Immunological mechanisms underneath the efficacy of cancer therapy","volume":"4","author":"Galluzzi","year":"2016","journal-title":"Cancer Immunol Res"},{"issue":"4","key":"10.1016\/j.acra.2024.09.061_bib32","doi-asserted-by":"crossref","first-page":"1247","DOI":"10.1002\/hep.30889","article-title":"Dual programmed death receptor-1 and vascular endothelial growth factor receptor-2 blockade promotes vascular normalization and enhances antitumor immune responses in hepatocellular carcinoma","volume":"71","author":"Shigeta","year":"2020","journal-title":"Hepatology"},{"issue":"3","key":"10.1016\/j.acra.2024.09.061_bib33","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1016\/j.ccell.2023.02.016","article-title":"The evolving tumor microenvironment: from cancer initiation to metastatic outgrowth","volume":"41","author":"de Visser","year":"2023","journal-title":"Cancer Cell"},{"issue":"3","key":"10.1016\/j.acra.2024.09.061_bib34","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1016\/j.immuni.2024.02.007","article-title":"CD4+ T cell activation distinguishes response to anti-PD-L1+anti-CTLA4 therapy from anti-PD-L1 monotherapy","volume":"57","author":"Franken","year":"2024","journal-title":"Immunity"},{"key":"10.1016\/j.acra.2024.09.061_bib35","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2021.107929","article-title":"PD-1 inhibitor combined with apatinib modulate the tumor microenvironment and potentiate anti-tumor effect in mice bearing gastric cancer","volume":"99","author":"Chen","year":"2021","journal-title":"Int Immunopharmacol"},{"key":"10.1016\/j.acra.2024.09.061_bib36","doi-asserted-by":"crossref","DOI":"10.1016\/j.pharmthera.2022.108114","article-title":"Targeting myeloid-derived suppressor cells to enhance natural killer cell-based immunotherapy","volume":"235","author":"Joshi","year":"2022","journal-title":"Pharmacol Ther"},{"issue":"2","key":"10.1016\/j.acra.2024.09.061_bib37","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1038\/s41571-023-00846-y","article-title":"Myeloid-derived suppressor cells in cancer and cancer therapy","volume":"21","author":"Lasser","year":"2024","journal-title":"Nat Rev Clin Oncol"},{"issue":"10","key":"10.1016\/j.acra.2024.09.061_bib38","doi-asserted-by":"crossref","first-page":"5380","DOI":"10.1172\/JCI137110","article-title":"Targeting tumor-associated macrophages and granulocytic myeloid-derived suppressor cells augments PD-1 blockade in cholangiocarcinoma","volume":"130","author":"Loeuillard","year":"2020","journal-title":"J Clin Invest"},{"issue":"17","key":"10.1016\/j.acra.2024.09.061_bib39","doi-asserted-by":"crossref","first-page":"2243","DOI":"10.2217\/fon-2020-1290","article-title":"Atezolizumab and bevacizumab for hepatocellular carcinoma: mechanism, pharmacokinetics and future treatment strategies","volume":"17","author":"Liu","year":"2021","journal-title":"Future Oncol"},{"issue":"1","key":"10.1016\/j.acra.2024.09.061_bib40","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1186\/s13045-021-01164-5","article-title":"Combination strategies to maximize the benefits of cancer immunotherapy","volume":"14","author":"Zhu","year":"2021","journal-title":"J Hematol Oncol"},{"issue":"8","key":"10.1016\/j.acra.2024.09.061_bib41","doi-asserted-by":"crossref","first-page":"1492","DOI":"10.1136\/gutjnl-2019-318934","article-title":"Randomised, multicentre prospective trial of transarterial chemoembolisation (TACE) plus sorafenib as compared with TACE alone in patients with hepatocellular carcinoma: TACTICS trial","volume":"69","author":"Kudo","year":"2020","journal-title":"Gut"},{"key":"10.1016\/j.acra.2024.09.061_bib42","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2024.102622","volume":"72","author":"Jin","year":"2024","journal-title":"EClinicalMedicine"},{"issue":"11","key":"10.1016\/j.acra.2024.09.061_bib43","doi-asserted-by":"crossref","first-page":"3590","DOI":"10.1097\/JS9.0000000000000652","article-title":"Clinico-characteristics of patients which correlated with preferable treatment outcomes in immunotherapy for advanced hepatocellular carcinoma: a systematic review and meta-analysis","volume":"109","author":"Wang","year":"2023","journal-title":"Int J Surg"},{"key":"10.1016\/j.acra.2024.09.061_bib44","doi-asserted-by":"crossref","DOI":"10.1016\/j.coph.2023.102362","article-title":"Hepatic arterial infusion chemotherapy for patients with hepatocellular carcinoma: applicability in Western countries","volume":"70","author":"He","year":"2023","journal-title":"Curr Opin Pharmacol"}],"container-title":["Academic Radiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1076633224007104?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1076633224007104?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,12]],"date-time":"2026-05-12T12:14:51Z","timestamp":1778588091000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1076633224007104"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8]]},"references-count":44,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2025,8]]}},"alternative-id":["S1076633224007104"],"URL":"https:\/\/doi.org\/10.1016\/j.acra.2024.09.061","relation":{},"ISSN":["1076-6332"],"issn-type":[{"value":"1076-6332","type":"print"}],"subject":[],"published":{"date-parts":[[2025,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Efficacy and Safety of HAIC-FOLFOX Plus Tyrosine Kinase Inhibitors and Immune Checkpoint Inhibitors as First-line Treatment for Unresectable Advanced Hepatocellular Carcinoma: A Systematic Review and Meta-Analysis","name":"articletitle","label":"Article Title"},{"value":"Academic Radiology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.acra.2024.09.061","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Association of Academic Radiology. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}